Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C treatments in India.
Read more about ‘Killead’s Patent Application Killed by the Indian Patent Office!Tag: Pharmaceutical patents
Roche’s backbone rendered brittle by Indian Patent Office
The Indian Patent Office has revoked Roche’s patent on Bonviva after Cipla challenged its validity, citing a lack of inventive step and patentability. This decision highlights critical aspects of Indian pharmaceutical patent law and its impact on international drug companies.
Read more about Roche’s backbone rendered brittle by Indian Patent OfficeSpecial 301 Report: Chapter V. Inventive Step & 3(d) – Comprehending Apprehension or Apprehending Comprehension?
This post critically examines whether Section 3d serves as an extension of the inventive step analysis or as a separate requirement under Indian patent law. It discusses the legal and judicial perspectives on TRIPs compliance and the nuanced challenges in pharmaceutical patentability.
Read more about Special 301 Report: Chapter V. Inventive Step & 3(d) – Comprehending Apprehension or Apprehending Comprehension?The 3D Effect of Novartis Case on Genetic Inventions
The Novartis case established a strict test for therapeutic efficacy under Section 3(d) of the Indian Patents Act, influencing the patentability of genetic inventions. This post examines the impact on gene sequence patents and the ongoing legal debate regarding their compliance with Indian patent law.
Read more about The 3D Effect of Novartis Case on Genetic Inventions